Literature DB >> 15313892

S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer.

Sven Diederichs1, Etmar Bulk, Björn Steffen, Ping Ji, Lara Tickenbrock, Kerstin Lang, Kurt S Zänker, Ralf Metzger, Paul M Schneider, Volker Gerke, Michael Thomas, Wolfgang E Berdel, Hubert Serve, Carsten Müller-Tidow.   

Abstract

Distant metastasis is the predominant cause of death in early-stage non-small cell lung cancer (NSCLC). Currently, it is impossible to predict the occurrence of metastasis at early stages and thereby separate patients who could be cured by surgical resection alone from patients who would benefit from additional chemotherapy. In this study, we applied a comparative microarray approach to identify gene expression differences between early-stage NSCLC patients whose cancer ultimately did or did not metastasize during the course of their disease. Transcriptional profiling of 82 microarrays from two patient groups revealed differential expression of several gene families including known predictors of metastasis (e.g., matrix metalloproteinases). In addition, we found S100P, S100A2, trypsinogen C (TRY6), and trypsinogen IVb (PRSS3) to be overexpressed in tumors that metastasized during the course of the disease. In a third group of 42 patients, we confirmed the induction of S100 proteins and trypsinogens in metastasizing tumors and its significant correlation with survival by real-time quantitative reverse transcription-PCR. Overexpression of S100A2, S100P, or PRSS3 in NSCLC cell cultures led to increased transendothelial migration, corroborating the role of S100A2, S100P, and PRSS3 in the metastatic process. Taken together, we provide evidence that expression of S100 proteins and trypsinogens is associated with metastasis and predicts survival in early stages of NSCLC. For the first time, this implicates a role of S100 proteins and trypsinogens in the metastatic process of early-stage NSCLC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313892     DOI: 10.1158/0008-5472.CAN-04-2004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.

Authors:  Tariq Shah; Ioannis Stasinopoulos; Flonne Wildes; Samata Kakkad; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

Review 2.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

3.  Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.

Authors:  Sima Azizmohammadi; Aghdas Safari; Mehri Seifoleslami; Rahman Ghaffarzadegan Rabati; Mohsen Mohammadi; Hamid Yahaghi; Susan Azizmohammadi
Journal:  Tumour Biol       Date:  2015-12-10

4.  Loss of S100 antigenicity in metastatic melanoma.

Authors:  Dara L Aisner; Ajay Maker; Steven A Rosenberg; David M Berman
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

Review 5.  Genomics of lung cancer may change diagnosis, prognosis and therapy.

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

6.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

7.  Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.

Authors:  Seung-Wook Kim; Kyounga Cheon; Chang-Hoon Kim; Joo-Heon Yoon; David H Hawke; Ryuji Kobayashi; Ludmila Prudkin; Ignacio I Wistuba; Reuben Lotan; Waun Ki Hong; Ja Seok Koo
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

Review 9.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

10.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.